BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lange N, Dufour JF. Changing Epidemiology of HCC: How to Screen and Identify Patients at Risk? Dig Dis Sci 2019;64:903-9. [PMID: 30863952 DOI: 10.1007/s10620-019-05515-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Liao X, Bu Y, Jia Q. Traditional Chinese medicine as supportive care for the management of liver cancer: Past, present, and future. Genes Dis 2020;7:370-9. [PMID: 32884991 DOI: 10.1016/j.gendis.2019.10.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
2 Signore G, Nicod-lalonde M, Prior JO, Bertagna F, Muoio B, Giovanella L, Furlan C, Treglia G. Detection rate of radiolabelled choline PET or PET/CT in hepatocellular carcinoma: an updated systematic review and meta-analysis. Clin Transl Imaging 2019;7:237-53. [DOI: 10.1007/s40336-019-00332-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Wang X, Chen Y, Dong K, Ma Y, Jin Q, Yin S, Zhu X, Wang S. Effects of FER1L4-miR-106a-5p/miR-372-5p-E2F1 regulatory axis on drug resistance in liver cancer chemotherapy. Mol Ther Nucleic Acids 2021;24:449-61. [PMID: 33868788 DOI: 10.1016/j.omtn.2021.02.006] [Reference Citation Analysis]
4 Pu J, Wu X, Wu Y, Shao Z, Luo C, Tang Q, Wang J, Wei H, Lu Y. Anti-oncogenic effects of SOX2 silencing on hepatocellular carcinoma achieved by upregulating miR-222-5p-dependent CYLD via the long noncoding RNA CCAT1. Aging (Albany NY) 2021;13:12207-23. [PMID: 33952719 DOI: 10.18632/aging.103797] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Huang PS, Chang CC, Wang CS, Lin KH. Functional roles of non-coding RNAs regulated by thyroid hormones in liver cancer. Biomed J 2021;44:272-84. [PMID: 33077406 DOI: 10.1016/j.bj.2020.08.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Dewdney B, Alanazy M, Gillman R, Walker S, Wankell M, Qiao L, George J, Roberts A, Hebbard L. The effects of fructose and metabolic inhibition on hepatocellular carcinoma. Sci Rep 2020;10:16769. [PMID: 33028928 DOI: 10.1038/s41598-020-73653-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Dufour J. Le carcinome hépatocellulaire. Schweiz Gastroenterol 2020;1:18-22. [DOI: 10.1007/s43472-020-00005-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Hong JH, Lee K, Kim J, Ahn KM. Prognosis of hepatocellular carcinoma metastasizing to the oral cavity. Maxillofac Plast Reconstr Surg 2021;43:9. [PMID: 33689049 DOI: 10.1186/s40902-021-00294-7] [Reference Citation Analysis]
9 Ho C, Lin K, Shen R, Gu D, Lee S, Su W, Jou Y. Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma. Computational and Structural Biotechnology Journal 2022. [DOI: 10.1016/j.csbj.2022.04.008] [Reference Citation Analysis]
10 Liu H, Li D, Zhou L, Kan S, He G, Zhou K, Wang L, Chen M, Shu W. LMNA functions as an oncogene in hepatocellular carcinoma by regulating the proliferation and migration ability. J Cell Mol Med 2020;24:12008-19. [PMID: 32896989 DOI: 10.1111/jcmm.15829] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]